close
Fox News Flash top headlines are here. Check out what’s clicking on Foxnews.com.
AstraZeneca said on Friday its and Daiichi Sankyo’s cancer drug Enhertu was recommended by the European Medicines Agency’s human medicines committee as a monotherapy to treat patients with a type of non-small cell lung cancer (NSCLC).
The recommendation is based on the mid-stage data where Enhertu showed a confirmed objective response rate of 49% and a median duration of response of 16.8 months in patients previously treated for lung cancer.
EU INITIATES ASSESSMENT OF HUMAN AND LABOR RIGHTS IN BURMA
AstraZeneca’s cancer medicine Enhertu, a drug developed jointly with Japan’s Daiichi Sankyo, is pictured in an undated handout image obtained by Reuters on June 27, 2022. (AstraZeneca/Handout via REUTERS/File photo)
CLICK HERE TO GET THE FOX NEWS APP
The drug is already approved in the European Union as a treatment for patients with an advanced form of breast cancer.
Recommendations made by the human medicines committee will have to be formally approved by the European Commission.
Amazon has agreed to pay $2.5 billion to settle allegations brought by the Federal Trade…
Sportswear and fitness brand Under Armour is investigating claims of a massive data breach after…
IN TODAY’S NEWSLETTER: - Amazon to cut 16,000 roles as it looks to invest in…
YouTube is rolling out new parental controls designed to give families more say over how…
What happens when artificial intelligence (AI) moves from painting portraits to designing homes? That question…
Apple often promotes the App Store as a secure place to download apps. The company…